On February 11, the DOJ announced a $7.9 million settlement with a Delaware-based pharmaceutical manufacturer for allegedly violating the False Claims Act by engaging in a kickback scheme with a pharmacy benefits manager corporation. The pharmaceutical manufacturer denies the DOJ's allegations that it paid $40 million to a pharmacy benefits manager corporation in exchange for "sole and exclusive" recommendation of a certain drug.
http://ift.tt/1CTqxlh
http://ift.tt/1CTqxlh
No comments:
Post a Comment